Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAdar poonawala

    Adar Poonawala

    Jump to

    • Serum's HPV vaccine to join govt's immunisation program later this year, exports in 2026-27: CEO

      While discussing the financial constraints of the vaccine industry, Poonawalla called for relaxing price caps to encourage innovation and growth.

    • Dharma's deal with Adar Poonawalla is 'Good Newwz' for Bollywood, likely to fuel big projects: Experts

      Analysts have pointed out that this year the dominance of Hindi language films has considerably weakened and the industry is in dire need of a rebound.

    • Serum Institute in talks with Danish firm to import monkeypox vaccine

      In case of a collaboration it could take two to three months to import the vaccine into the country, Poonawalla said in an interview to news channel NDTV.

    • World's biggest vaccine maker Serum halts production with 200 million doses spare

      The Serum Institute has produced more than one billion doses of Covishield -- its version of the AstraZeneca jab -- and is a major supplier to the Covax global inoculation programme for poorer countries.

    • Serum CEO Adar Poonawalla says COVID-19 vaccine for children in six months

      The Novavax shot, which the world's largest producer of vaccines calls Covovax, has shown good results in trials in children aged three and older, Adar Poonawalla told a virtual conference organised by the Confederation of Indian Industry.

    • What ‘second wave’ means for investors in Indian pharma

      Multi-year opportunity awaits Indian vaccine manufacturers such as DRL, Gland Pharma, Aurobindo Pharma and Cadila Pharma

    • Will send Covishield to Canada in less than a month, says SII's Adar Poonawalla

      Covishield is the brand name for the AstraZeneca-Oxford University COVID-19 vaccine. Prime Minister Narendra Modi on February 10 had assured his Canadian counterpart Justin Trudeau that India would do its best to facilitate supplies of COVID vaccines sought by Canada.

    • The vaccine controversy deals a big blow to India’s global profile

      The unseemly hurry to hand out approvals without adequate data in at least one case has long term implications for the Indian vaccine industry’s reputation

    • How prepared is India for a COVID-19 vaccine?

      As things stand, the COVID-19 vaccination programme will be an enormous national project. An acceleration of the timetable may turn out to be the biggest effort the Indian State has made in its history

    • Anand Mahindra's tweet on 'Big V' vaccine: Here's how Adar Poonawalla responded

      In a tweet on August 2, Mahindra had joked about a vaccine called "Big V", a reference to the Amitabh Bachchan's popular nickname "Big B" and how all of India needs a dose of that.

    • Exclusive: Poonawalla family's Serum Institute looks to raise $1 billion for big-ticket COVID-19 vaccine project

      Investment banks Goldman Sachs, Citi and Avendus Capital have been engaged as advisors for the process by the privately held vaccine manufacturer, say sources.

    • Interview - Serum Institute's Adar Poonawala plans new vaccines and an NBFC

      Adar Poonawala took over from his father Cyrus, to guide the fortunes of the group. In an exclusive interview, he spoke about some of the group’s initiatives.

    • Looking for bigger partnership with Cipla: Serum Institute

      Adar Poonawala, CEO of Serum Institute, believes that a bigger partnership with Cipla will create a big Indian conglomerate. However, he added that the Cipla promoters currently have no plans for a merger and acquisition.

    • Cipla-Serum merger unlikely in near future: Adar Poonawala

      Serum Institute CEO Adar Poonawala has told CNBC-TV18 that Cipla and Serum will not be merging anytime soon. Cipla and Serum Institute have joined hands to sell products jointly across various countries in the world.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347